KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $25.2 million.

  • Recursion Pharmaceuticals' Share-based Compensation rose 3829.51% to $25.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $118.2 million, marking a year-over-year increase of 7650.99%. This contributed to the annual value of $81.7 million for FY2024, which is 5267.93% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Share-based Compensation stood at $25.2 million for Q3 2025, which was up 3829.51% from $26.2 million recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Share-based Compensation peaked at $36.1 million during Q1 2025, and registered a low of $1.8 million during Q1 2021.
  • Its 5-year average for Share-based Compensation is $14.0 million, with a median of $11.8 million in 2023.
  • In the last 5 years, Recursion Pharmaceuticals' Share-based Compensation skyrocketed by 59141.74% in 2021 and then surged by 673.31% in 2022.
  • Quarter analysis of 5 years shows Recursion Pharmaceuticals' Share-based Compensation stood at $4.3 million in 2021, then soared by 77.26% to $7.7 million in 2022, then surged by 109.04% to $16.1 million in 2023, then surged by 91.37% to $30.8 million in 2024, then fell by 18.0% to $25.2 million in 2025.
  • Its Share-based Compensation stands at $25.2 million for Q3 2025, versus $26.2 million for Q2 2025 and $36.1 million for Q1 2025.